See more : Saipem SpA (SAPMD) Income Statement Analysis – Financial Results
Complete financial analysis of Newron Pharmaceuticals S.p.A. (NP5.DE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Newron Pharmaceuticals S.p.A., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Dalian Haosen Equipment Manufacturing Co., Ltd. (688529.SS) Income Statement Analysis – Financial Results
- Chanjet Information Technology Company Limited (1588.HK) Income Statement Analysis – Financial Results
- Sarissa Capital Acquisition Corp. (SRSA) Income Statement Analysis – Financial Results
- ArrowMark Financial Corp. (BANX) Income Statement Analysis – Financial Results
- General Finance Corporation (GFNCP) Income Statement Analysis – Financial Results
Newron Pharmaceuticals S.p.A. (NP5.DE)
About Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 24 full-time employees. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.06M | 6.09M | 5.76M | 5.26M | 7.04M | 4.03M | 13.43M | 6.73M | 2.38M | 1.56M | 3.54M | 8.92M | 280.00K | 806.00K | 2.54M | 3.93M | 4.02M | 1.19M | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 295.00K | 1.43M | 1.37M | 0.00 | 2.63M | 1.26M | 477.00K | 269.00K | 28.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 9.06M | 6.09M | 5.76M | 4.96M | 5.61M | 2.65M | 13.43M | 4.09M | 1.12M | 1.08M | 3.27M | 8.90M | 280.00K | 806.00K | 2.54M | 3.93M | 4.02M | 1.19M | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 94.39% | 79.75% | 65.91% | 100.00% | 60.84% | 46.97% | 69.36% | 92.40% | 99.69% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 13.15M | 12.01M | 10.73M | 10.35M | 12.01M | 4.94M | 8.60M | 12.40M | 18.45M | 6.02M | 4.54M | 3.53M | 3.82M | 15.92M | 18.54M | 12.88M | 8.20M | 11.49M | 10.60M |
| General & Administrative | 3.98M | 3.54M | 3.49M | 4.93M | 6.42M | 5.15M | 3.96M | 4.59M | 4.29M | 3.61M | 3.79M | 4.15M | 6.90M | 6.45M | 8.47M | 9.26M | 9.45M | 6.62M | 4.54M |
| Selling & Marketing | 80.00K | 81.00K | 38.00K | 331.00K | 634.00K | 406.00K | 708.00K | 513.00K | 53.00K | 53.00K | 15.00K | 62.00K | 51.00K | 73.00K | 86.00K | 115.00K | 131.00K | 0.00 | 0.00 |
| SG&A | 4.06M | 3.62M | 3.53M | 5.26M | 7.05M | 5.56M | 4.66M | 5.10M | 4.34M | 3.67M | 3.81M | 4.21M | 6.95M | 6.52M | 8.55M | 9.37M | 9.58M | 6.62M | 4.54M |
| Other Expenses | 3.47M | 3.77M | 3.86M | 7.42M | 7.45M | 7.14M | 4.51M | 4.55M | 3.99M | 3.09M | 2.97M | 3.87M | -10.00K | 0.00 | 0.00 | 0.00 | 0.00 | -164.00K | -67.00K |
| Operating Expenses | 20.69M | 19.40M | 18.12M | 23.03M | 26.51M | 17.63M | 17.77M | 22.05M | 26.78M | 12.77M | 11.32M | 11.62M | 6.76M | 22.45M | 27.10M | 22.25M | 17.78M | 17.94M | 15.08M |
| Cost & Expenses | 20.69M | 19.40M | 18.12M | 23.32M | 27.94M | 19.00M | 17.77M | 22.05M | 26.78M | 12.77M | 11.32M | 11.62M | 6.76M | 22.45M | 27.10M | 22.25M | 17.78M | 17.94M | 15.08M |
| Interest Income | 179.00K | 56.00K | 54.00K | 61.00K | 191.00K | 132.00K | 204.00K | 238.00K | 120.78K | 0.00 | 0.00 | 84.00K | 72.00K | 31.00K | 274.79K | 2.23M | 2.57M | 310.73K | 0.00 |
| Interest Expense | 4.17M | 3.95M | 2.92M | 2.24M | 572.00K | 56.00K | 85.00K | 132.00K | 1.17M | 0.00 | 0.00 | 16.00K | 6.00K | 33.00K | 69.79K | 268.50K | -19.91K | -40.27K | 0.00 |
| Depreciation & Amortization | 201.00K | 204.87K | 217.80K | 216.66K | 210.80K | 48.15K | 45.54K | 33.55K | 71.00K | 33.00K | 39.00K | 63.00K | 88.00K | 149.00K | 524.00K | 271.00K | 213.00K | 0.00 | 0.00 |
| EBITDA | -11.72M | -13.32M | -12.00M | -17.16M | -20.85M | -14.79M | -4.05M | -15.29M | -24.46M | -10.80M | -7.71M | -2.63M | -6.34M | -21.52M | -24.03M | -18.05M | -13.47M | -16.73M | -15.08M |
| EBITDA Ratio | -129.40% | -218.62% | -204.04% | -326.36% | -275.40% | -370.58% | -38.49% | -223.60% | -997.69% | -718.18% | -218.62% | -27.10% | -2,261.43% | -2,666.38% | -945.40% | -458.89% | -336.43% | -1,406.55% | 0.00% |
| Operating Income | -11.63M | -13.30M | -12.36M | -18.07M | -20.90M | -14.98M | -4.35M | -15.33M | -24.40M | -11.22M | -7.78M | -2.70M | -6.48M | -21.64M | -24.56M | -18.32M | -13.68M | -16.75M | -15.08M |
| Operating Income Ratio | -128.40% | -218.28% | -214.46% | -343.59% | -296.95% | -372.12% | -32.37% | -227.85% | -1,025.21% | -720.30% | -219.72% | -30.22% | -2,315.00% | -2,684.86% | -966.01% | -465.78% | -339.99% | -1,406.55% | 0.00% |
| Total Other Income/Expenses | -4.57M | -4.17M | -2.53M | -1.55M | 737.00K | -41.00K | -955.00K | 121.00K | -583.00K | 492.00K | 63.00K | 200.00K | 45.00K | -33.00K | 205.00K | 1.96M | 2.59M | 351.00K | 157.00K |
| Income Before Tax | -16.20M | -17.47M | -14.88M | -19.62M | -20.16M | -15.02M | -5.30M | -15.20M | -24.98M | -10.72M | -7.71M | -2.50M | -6.44M | -21.67M | -24.35M | -16.36M | -11.09M | -16.40M | -14.92M |
| Income Before Tax Ratio | -178.87% | -286.71% | -258.31% | -373.11% | -286.47% | -373.14% | -39.48% | -226.05% | -1,049.71% | -688.70% | -217.94% | -27.98% | -2,298.93% | -2,688.96% | -957.95% | -415.87% | -275.55% | -1,377.08% | 0.00% |
| Income Tax Expense | 24.00K | 21.00K | 17.00K | 1.38M | 45.00K | 16.00K | -19.00K | 33.00K | -2.17M | -628.00K | -615.00K | -122.00K | 8.00K | -1.13M | -870.00K | 8.00K | 1.00K | -351.00K | -157.00K |
| Net Income | -16.22M | -17.49M | -14.90M | -21.00M | -20.21M | -15.04M | -5.28M | -15.24M | -22.82M | -10.10M | -7.10M | -2.38M | -6.45M | -20.55M | -23.48M | -16.36M | -11.09M | -16.40M | -14.92M |
| Net Income Ratio | -179.13% | -287.05% | -258.61% | -399.35% | -287.11% | -373.54% | -39.34% | -226.54% | -958.66% | -648.36% | -200.57% | -26.61% | -2,301.79% | -2,549.01% | -923.72% | -416.07% | -275.57% | -1,377.08% | 0.00% |
| EPS | -0.91 | -0.98 | -0.84 | -1.18 | -1.13 | -0.84 | -0.32 | -1.04 | -1.66 | -0.80 | -0.62 | -0.29 | -0.89 | -3.11 | -3.86 | -2.74 | -1.90 | -4.33 | -5.29 |
| EPS Diluted | -0.91 | -0.98 | -0.84 | -1.18 | -1.13 | -0.84 | -0.32 | -1.04 | -1.66 | -0.80 | -0.62 | -0.29 | -0.89 | -3.11 | -3.86 | -2.74 | -1.90 | -4.33 | -5.29 |
| Weighted Avg Shares Out | 17.85M | 17.85M | 17.85M | 17.85M | 17.85M | 17.84M | 16.30M | 14.69M | 13.72M | 12.69M | 11.51M | 8.16M | 7.26M | 6.61M | 6.09M | 5.96M | 5.83M | 3.79M | 2.82M |
| Weighted Avg Shares Out (Dil) | 17.85M | 17.85M | 17.85M | 17.85M | 17.85M | 17.84M | 16.30M | 14.69M | 13.72M | 12.69M | 11.51M | 8.16M | 7.26M | 6.61M | 6.09M | 5.96M | 5.83M | 3.79M | 2.82M |
Source: https://incomestatements.info
Category: Stock Reports